Syntax Research, Inc. C4 Therapeutics, Inc. Transaction History
Syntax Research, Inc.
- $141 Billion
- Q2 2025
A detailed history of Syntax Research, Inc. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Syntax Research, Inc. holds 1,000 shares of CCCC stock, worth $2,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000
Previous 1,000
-0.0%
Holding current value
$2,500
Previous $1.6 Million
10.63%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
118Shares Held
62.2MCall Options Held
18.8KPut Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.1MShares$17.7 Million4.2% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$17.4 Million0.92% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$17.1 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.72MShares$16.8 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$11.4 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $122M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...